Thanks TommyD.
Bit confusing as the language used in the linkedin post indicates it was a presentation of in vitro data previously shared, this has to be referring to RNS from 24/05/21 right? data from the testing Viroclinics-DDL conducted?
"presentation of our previously shared in vitro data"
However the abstract from the presentation language reads as though porton down conducted the tests.
"In this study we tested the antiviral efficacy of IFN-β1a, in vitro, against a variety of SARS-CoV-2
variants"
Another piece of the puzzle we still haven't had any any clarification on was from the UKRI 22-23 annual report:
"Spinout develops faster diagnoses and alternative treatments for lung infections
Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow"
https://assets.publishing.service.gov.uk/media/64bf8a7fd4051a000d5a9242/ukri-annual-report-accounts-2022-2023-print-ready.pdf
Also to note: "UK Research and Innovation is a non-departmental public body of the Government of the United Kingdom that directs research and innovation funding, funded through the science budget of the Department for Science, Innovation and Technology. "
If I remember correctly TommyD was first to post this find on here if it was somebody else my apologies.
What I'm struggling to get my head around is why would UKHSA Porton Down now go through the trouble of re-testing SNG001 in vitro against variants of covid when it had already been confirmed it was effective against all know variants by Viroclinics-DDL in the Netherlands.
Maybe it was UKHSA doing its due diligence to confirm SNG001's virus/variant agnostic properties before supporting with more govt back funding or trials?
Https://www.ualberta.ca/folio/2024/02/new-class-of-antivirals-works-against-broad-range-of-rna-viruses.html
Nothing on here Synairgen specific but interesting to see others are also investigating Interferon as a broad-spectrum anti-viral.
Https://www.isrctn.com/ISRCTN49183956
Editorial Notes
27/02/2024: The recruitment end date has been changed from 30/11/2023 to 31/12/2024.
Https://synairgen.ams3.digitaloceanspaces.com/230629-Synairgen-AGM-2023_FINAL.pdf
I remember the question was asked last week if it was confirmed that universal study will be testing for Autoantibodies. Going back through the AGM presentation slides it did clarify the below:
"Assessment of impact of risk factors for a poor outcome:
− Autoantibodies against other type I IFNs (α and ω)
− Presence of naturally occurring antibodies against other type I IFNs associated with a poorer clinical outcome in patients with SARSCoV-2 and more recently flu infections."
@Mani my opinion for whatever it is worth is that because the trial numbers are going to be on the smaller side and recruiting highly targeted patients this wont make much of a difference if it is summer, winter, spring or autumn.
If this was a phase 3 which require large volumes of patients then winter would be ideal due tot he higher influx of hospitalised patients.
From the blogpost from Jan 2023 Prof Tom Wilko mentions "we are bringing together a unique consortium of companies willing to work pre-competitively"
We already know for sure the below are included in the "unique consortium":
Uni of Southampton CTU
Synairgen
Janssen
AstraZeneca
From the UKRI annual report I posted yesterday it mentions:
"Spinout develops faster diagnoses and alternative treatments for lung infections
Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow"
As far as we know Synairgen isn't in the diagnostics business so it leads me to believe there are more players already involved in the consortium Prof TW mentioned, we know Synairgen plans to collaborate with Casanova Labs which would include another partner who will be manufacturing the assays.
Who else could be in this unique concortium? TopMD?
Did we ever get to the bottom of what the below meant from the UKRI Annual Report 2022-2023. very interesting wording.
"Spinout develops faster diagnoses and alternative treatments for lung infections
Synairgen’s COVID-19 trial reduced the waiting time of a point-of-care test used to recruit patients to within one hour, a dramatic reduction from one day, and had positive impacts on patient flow"
If I remember correctly TommyD was firsy to posy this find on this BB if it was somebody else my apologies.
https://assets.publishing.service.gov.uk/media/64bf8a7fd4051a000d5a9242/ukri-annual-report-accounts-2022-2023-print-ready.pdf
One thing we know is Synairgen have a track record of not hitting targets and timescales slipping due to things under their control and not under their control, this maybe just how things are in the pharma world and I don't believe SNG have the sway of BP to get things to move quick with regulators etc.
I'm beginning to think the company will be waiting until all data from circa 1,000 subjects has been collected and assessed from UNIVERSAL before starting P2's to give them the fairest shot at cracking the planned trials, personally I'm setting myself up to expect further delays and for the P2s to kick off in early 2025 and if earlier then that is even better.
Https://www.linkedin.com/posts/mirimus_researchvolunteers-volunteer-medicalresearch-activity-7103389200330223616-55Q4
5 Months ago on linked in: "Join Mirimus research on autoantibodies and help advance medical research"
Mirimus is on the forefront of innovation, exploring autoantibodies, infections, and autoimmune diseases. We're calling on volunteers to contribute to this exciting journey. Your participation could lead to groundbreaking discoveries that shape the future of medicine.
According to the below link Jean-Laurent Casanova has a consulting role or is on the scientific advisory board at Mirimus:
https://rupress.org/jem/pages/editors-and-staff
Eduardo J. Garcia Reino, PhD also is an associate director has link to Rockefeller University which Casanova labs operates out of.
https://www.linkedin.com/in/eduardo-j-garcia-reino-phd-714b0287
Might be something to this.
2024 12 January
- Prof Tom Wilkinson: Developing new approaches to understand and treat inflammatory respiratory disease - a drive for new technology
- Dr Tommaso Morelli: Respiratory viral infections in hospitalised adults - preliminary findings for the UNIVERSAL study
Maybe a stretch but does anybody have University of Southampton credentials to access the below 2 talks held by Prof Tom Wilkinson and Dr Tommaso Morelli which took place on the 12th of Jan 2024?
Would like to see if there was anything new from the universal study shared in these talks.
https://www.southamptonbrc.nihr.ac.uk/brc-forum
Doc.D from the first 313 subjects within the UNIVERSAL Study one thing they did find that they highlighted in the preliminary data:
"Conclusion: Common RVIs including RhV cause considerable morbidity. Lymphopenia and CRP>55 mg/L were associated with more severe disease in adults admitted with RVI. More precise characterisation of biomarkers associated with severity is an essential prerequisite to novel therapeutics development."
Not a clue what it means or if it is even a new finding not already known to the eggheads.
https://thorax.bmj.com/content/78/Suppl_4/A77.2.abstract